Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
US-Präsident setzt auf die Solana Blockchain! Diese Krypto-Perle profitiert enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
533 Leser
Artikel bewerten:
(2)

HLTH Europe: HLTH Is Coming: Preeminent Health Innovation Event In The U.S. Launches In Europe & Announces First Supporters

Finanznachrichten News

LONDON, June 19, 2023 /PRNewswire/ -- HLTH Inc. today announced their early confirmed speakers, sponsors and partners a full year ahead of the inaugural HLTH Europe, which takes place 17-20 June 2024 at RAI Amsterdam. Organisations from across Europe and the U.S. are supporting HLTH's newest event.

HLTH Europe

HLTH (pronounced "health") has quickly established itself as the definitive healthcare event in the US. Founded by serial entrepreneur and investor, Jonathan Weiner, HLTH will be the third event he has founded to be brought to Europe at scale.

Weiner, who also co-founded industry-defining events Money20/20 and Shoptalk, said 'The last few years have shown that collaboration across healthcare is critical. From providers and payers , through patient groups and life sciences, to policy makers, startup founders and investors, now more than ever, healthcare must focus on solving the immediate challenges systems are facing. HLTH's events bring together the key players, at scale, to navigate the transformative opportunities that lie ahead and ultimately ensure better health outcomes.'

HLTH Europe's agenda will profile the individuals and organisations catalysing action and inspiring change across the entire European health ecosystem. HLTH Europe will focus on tackling the difficult conversations and exploring the many opportunities in European health today,' said Lina Behrens, Head of Content, HLTH Europe.

Early speakers confirmed for HLTH Europe include:

  • Ian Abbs, CEO & Chief Medical Officer, Guy's and St Thomas' NHS Foundation Trust (United Kingdom)
  • Lisa Banks, VP, Digital Health & Innovation, R&D Digital & Tech, GSK (Belgium)
  • Chris Bischoff, Managing Director, General Catalyst (United Kingdom)
  • Eric Carreel, Founder & Chairman, Withings (France)
  • Thomas Clozel, Co-Founder & CEO, Owkin (France)
  • Maris Dreimanis, Head of Digital Transformation, The National Health Service of Latvia (Latvia)
  • Nadine Hachach-Haram, Founder & CEO, Proximie and NHS Surgeon (United Kingdom)
  • Nicolas Hantzsch, Chief Operating Officer & Co-Founder, Patient21 (Germany)
  • Adama Ibrahim, VP Digital Strategy and Change Management, Novo Nordisk (Denmark)
  • Alyssa Jaffee, Partner, 7wireVentures (USA)
  • Stefanie Kemp, Chief Transformation Officer, Sana Kliniken (Germany)
  • Heyo Kroemer, CEO, Charité (Germany)
  • Rana Lonnen, Managing Director, dRx Capital, Novartis (Switzerland)
  • Sophie Park, Managing Director, Bayer G4A (USA)
  • Marlies P Schijven, Professor of Surgery, Chair on Digital Health, Amsterdam University Medical Centers (Netherlands)
  • Johannes Schildt, CEO & Co-Founder, Kry/Livi (Sweden)
  • Dan Vahdat, CEO & Founder, Huma (United Kingdom)
  • Eyal Zimlichman, Chief Transformation and Chief Innovation Officer,Sheba Medical Center (Israel)

'We've been blown away by the early support for HLTH Europe. To be more than a year out, and to have sponsors on board like Aptar, AlbionVC, ANDHealth, AWS, Headspace, Infermedica, Phillips, Propeller Health, ResMed, and Withings is astonishing.' said Katy Fryatt, Managing Director, HLTH Europe. 'These early sponsors are 'the first on the dance floor', and we're grateful for their support as we build HLTH in Europe.'

HLTH has also secured a number of key strategic partnerships with European and US organisations, including ECH Alliance, Digital Salutem, Galen Growth, HealthXL, HolonIQ and Healthcare World.

Imagery
Media Image Album (Open)

About HLTH Inc & HLTH Europe

HLTH Inc.'s mission is to empower individuals within the healthcare ecosystem to solve complex challenges, foster innovation, and catalyse change for good and for all.

Founded in 2018, HLTH Inc.'s flagship event, HLTH unites over 10,000 healthcare leaders in Las Vegas each autumn and has quickly become the U.S.'s number one event in healthcare innovation. Led by an expert local team (based in London and Berlin), HLTH Europe will combine the best of HLTH's U.S. events with the unique needs of the complex European health markets, to catalyse change and highlight opportunities for improving experiences and outcomes across the continent.

The inaugural HLTH Europe will take place at RAI, Amsterdam from 17-20 June and is projecting 3,500 attendees, 250 speakers and 350 sponsors.

Media Contact:
Henry Stoneley
henry@hlth.com
Head of UK & Netherlands
Contact no: (+44) 7900 896 725

Photo - https://mma.prnewswire.com/media/2105100/HLTH_Europe_Photo1.jpg
Photo - https://mma.prnewswire.com/media/2105101/HLTH_Europe_Photo2.jpg
Photo - https://mma.prnewswire.com/media/2105103/HLTH_Europe_Photo3.jpg
Logo - https://mma.prnewswire.com/media/2105102/4094202/HLTH_Europe_Logo.jpg

HLTH Europe

HLTH Europe

HLTH Europe 2024

Cision View original content:https://www.prnewswire.co.uk/news-releases/hlth-is-coming-preeminent-health-innovation-event-in-the-us-launches-in-europe--announces-first-supporters-301854286.html

© 2023 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.